BioCentury
ARTICLE | Clinical News

GRC 27864: Phase I start

April 14, 2014 7:00 AM UTC

Glenmark said it will "soon" begin a U.K. Phase I trial of oral GRC 27864. Glenmark is developing GRC 27864 under a 2012 deal with Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.) to develop PTGES...